This research reveals that high doses of colchicine inhibit NLRP3 inflammasome activation in COVID-19 and Influenza, suggesting a potential treatment for cytokine storm.
Despite the enormous theoretical progress, there is currently no effective treatment for the cytokine storm (CS) in COVID-19 and Influenza, which is due to hyperactivation of NOD-like receptor protein 3 inflammasome (NLRP3-I). According to our research, the only way to prevent or interrupt the CS is to administer high but safe doses of colchicine, which inhibits NLRP3-I/CS.
No takes yet. Share an insight, caveat, or question.
Mitev et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: